Identification of distinct phenotypes related to benralizumab responsiveness in patients with severe eosinophilic asthma

To characterize the clinical phenotypes of severe eosinophilic asthma based on early responsiveness to benralizumab in terms of forced expiratory volume in 1 second (FEV1) improvement. Sixty-four participants diagnosed with severe eosinophilic asthma and who had completed 4 months of benralizumab tr...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2021-03, Vol.16 (3), p.e0248305
Main Authors: Yamada, Hideyasu, Nakajima, Masayuki, Matsuyama, Masashi, Morishima, Yuko, Arai, Naoki, Hida, Norihito, Nakaizumi, Taisuke, Masuko, Hironori, Yatagai, Yohei, Saito, Takefumi, Hizawa, Nobuyuki
Format: Article
Language:English
Subjects:
Age
Analysis
Asthma
Biology and Life Sciences
Bronchodilators
Care and treatment
Cigarette smoking
Clinical trials
Cluster analysis
Demographics
Demography
Drug dosages
Editing
Ethics
Health services
Hypotheses
Immunoglobulin E
Immunosuppressive agents
Inflammation
Informed consent
Leukocytes (eosinophilic)
Medicine
Medicine and Health Sciences
Monoclonal antibodies
Obesity
Patients
Peripheral blood
Phenotype
Phenotypes
Physical Sciences
Research and Analysis Methods
Social Sciences
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To characterize the clinical phenotypes of severe eosinophilic asthma based on early responsiveness to benralizumab in terms of forced expiratory volume in 1 second (FEV1) improvement. Sixty-four participants diagnosed with severe eosinophilic asthma and who had completed 4 months of benralizumab treatment were included in this analysis. Pre-treatment clinical factors were compared between responders and non-responders according to improvements in ACT or FEV1. Correlations between the sums of increased Type 2-related inflammatory parameters and changes of ACT or FEV1 were also evaluated before and after the 4-month treatment. A two-step cluster analysis was performed to identify distinct phenotypes related to benralizumab responsiveness in terms of FEV1. At the 4-month timepoint, all parameters, except for FeNO, were significantly improved after benralizumab treatment. FEV1 responders were associated with higher levels of Type 2-related inflammatory parameters. An improvement in FEV1 but not in ACT was clearly associated with increases in the sums of increased type 2-related inflammation parameters (p = 0.0001). The cluster analysis identified 5 distinct phenotypes of severe eosinophilic asthma according to the variable FEV1 responsiveness to benralizumab. The greatest response was found in the distinct phenotype of severe eosinophilic asthma, which was characterized by modest increase in total IgE and FeNO relative to blood eosinophils with least exposure to smoking. This study, to the best of our knowledge, is the first cluster analysis to report distinct phenotypes related to clinical benralizumab response in a real-world population with severe eosinophilic asthma. These results may help to predict responsiveness to benralizumab in patients with severe eosinophilic asthma.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0248305